ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753

Its studies are mostly in Lymphoma, B-Cell, led by Gilead Sciences.

Drug pageAutologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 13, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences22 open or runningphase 3since Mar 13, 2026Jul 26, 2021Feb 2030phase 2 · NCT04989803

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2021First study: phase 2 study in Relapsed and/or Refractory B-cell LymphomaFirst studyNCT04989803 · 247 enrolled · United States, Australia, Canada and more
  2. Mar 13, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07479797 · 550 enrolled · United States, Australia, Belgium and more

Ahead

  1. Feb 2030Primary completion: phase 2 study in Relapsed and/or Refractory B-cell LymphomaNCT04989803
  2. May 2031Primary completion: phase 3 study in RecurrenceNCT07479797

TargetBeta

CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) with a ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07479797Recurrence · United States, Australia, Belgium and more3Active, not recruitingMay 2031550
NCT04989803Relapsed and/or Refractory B-cell Lymphoma · United States, Australia, Canada and more2Active, not recruitingFeb 2030247

How it is read

Names in the registry

  • “KITE-753”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.